{"id":477669,"date":"2020-04-03T12:00:01","date_gmt":"2020-04-03T12:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477669"},"modified":"2020-04-03T12:00:01","modified_gmt":"2020-04-03T12:00:01","slug":"cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast-2030_477669.html","title":{"rendered":"Cholangiocarcinoma (CCA) Market Insights, Epidemiology and Market Forecast 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585893244.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cholangiocarcinoma (CCA) Market Insights, Epidemiology and Market Forecast 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585893244.jpeg\" alt=\"Cholangiocarcinoma (CCA) Market Insights, Epidemiology and Market Forecast 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cholangiocarcinoma (CCA) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cholangiocarcinoma (CCA), historical and forecasted epidemiology as well as the Cholangiocarcinoma (CCA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight<\/strong> launched a new report on&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-market\" target=\"_blank\">Cholangiocarcinoma (CCA) &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/a>.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Cholangiocarcinoma (CCA) &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/strong>&#8221;&nbsp;report delivers an in-depth understanding of the Cholangiocarcinoma (CCA), historical and forecasted epidemiology as well as the Cholangiocarcinoma (CCA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/ead1a5ebd2aec18fc503738850afba9e.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key fact from the report:<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Among the EU5 countries,&nbsp;Germany&nbsp;had the highest incident population of Cholangiocarcinoma (CCA) with 4,471 cases, followed by&nbsp;Italy&nbsp;and the&nbsp;United Kingdom. On the other hand,&nbsp;Spain&nbsp;had the lowest incident population.&#8221;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:<\/strong>&nbsp;https:\/\/www.delveinsight.com\/sample-request\/cholangiocarcinoma-cca-market<\/p>\n<p style=\"text-align: justify;\"><strong>&#8220;Males are more prone to Cholangiocarcinoma&nbsp;than females in all countries. Cholangiocarcinoma&nbsp;overall incidence in both the genders is subjected to increase in the coming years&#8221;<\/strong><\/p>\n<p style=\"text-align: justify;\">Currently, Cholangiocarcinoma or Bile Duct Cancer market size for early-stage majorly includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy the following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.<\/p>\n<p style=\"text-align: justify;\"><strong>Key pharma players:<\/strong><br \/>1.&nbsp;Agios Pharmaceuticals<br \/>2.&nbsp;Bayer<br \/>3.&nbsp;Basilea Pharmaceutica<br \/>4.&nbsp;Delcath Systems<br \/>5.&nbsp;Hoffmann-La Roche<br \/>6.&nbsp;Incyte Corporation<br \/>and many others.<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs involved are:<\/strong><br \/>1.&nbsp;AG-120<br \/>2.&nbsp;Pemigatinib<br \/>3. Infigratinib<br \/>4.&nbsp;Regorafenib<br \/>5.&nbsp;LOXO-101<br \/>6.&nbsp;Entrectinib<br \/>and many others<\/p>\n<p style=\"text-align: justify;\"><strong>Request a free sample report:<\/strong>&nbsp;https:\/\/www.delveinsight.com\/sample-request\/cholangiocarcinoma-cca-market<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><br \/>1. Key Insights<br \/>2. Executive Summary of Cholangiocarcinoma (CCA)<br \/>3. Competitive Intelligence Analysis for Cholangiocarcinoma (CCA)<br \/>4. Cholangiocarcinoma (CCA): Market Overview at a Glance<br \/>5. Cholangiocarcinoma (CCA): Disease Background and Overview<br \/>6. Patient Journey<br \/>7. Cholangiocarcinoma (CCA) Epidemiology and Patient Population<br \/>8. Treatment Algorithm, Current Treatment, and Medical Practices<br \/>9. Unmet Needs<br \/>10. Key Endpoints of Cholangiocarcinoma (CCA) Treatment<br \/>11. Marketed Products<br \/>12. Emerging Therapies<br \/>13. Cholangiocarcinoma (CCA): Seven Major Market Analysis<br \/>14. Attribute analysis<br \/>15. 7MM: Market Outlook<br \/>16. Access and Reimbursement Overview of Cholangiocarcinoma (CCA)<br \/>17. KOL Views<br \/>18. Market Drivers<br \/>19. Market Barriers<br \/>20. Appendix<br \/>21. DelveInsight Capabilities<br \/>22. Disclaimer<br \/>23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight:<\/strong> <br \/>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Cholangiocarcinoma (CCA) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cholangiocarcinoma (CCA), historical and forecasted epidemiology as well as the Cholangiocarcinoma (CCA) market trends in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast-2030_477669.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-477669","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477669"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}